Current Report Filing (8-k) January 04 2023 - 04:
Post# of 72447
(Total Views: 610)
Posted On: 01/05/2023 8:26:25 PM
Current Report Filing (8-k)
January 04 2023 - 04:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 30, 2022
INNOVATION PHARMACEUTICALS INC.
(Exact Name of Registrant as Specified in Charter)
Nevada
001-37357
30-0565645
(State or Other Jurisdiction
(Commission File Number)
(IRS Employer of Incorporation)
Identification No.)
301 Edgewater Place - Suite 100
Wakefield, Massachusetts 01880
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code: (978) 921-4125
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered under Section 12(b) of the Exchange Act: none
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On December 30, 2022, Leo Ehrlich, Chief Executive Officer of Innovation Pharmaceuticals Inc. (the “Company”), surrendered 11,307,527 shares of the Company’s Class B common stock to the Company for individual tax planning purposes. Mr. Ehrlich received no consideration for the surrender of the shares.
Following the surrender of the shares, 4,333,936 shares of Class B common stock remain outstanding, all of which are held by Mr. Ehrlich. Each share of Class B common stock entitles the holder to ten votes per share and each share of Class A common stock entitles the holder to one vote per share on all matters submitted to the Company’s stockholders for a vote. The Class B common stock is convertible at any time by the holder into shares of Class A common stock on a share-for-share basis.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INNOVATION PHARMACEUTICALS INC.
Dated: January 4, 2023 By: /s/ Leo Ehrlich
Name:
Leo Ehrlich
Title: Chief Executive Officer
January 04 2023 - 04:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 30, 2022
INNOVATION PHARMACEUTICALS INC.
(Exact Name of Registrant as Specified in Charter)
Nevada
001-37357
30-0565645
(State or Other Jurisdiction
(Commission File Number)
(IRS Employer of Incorporation)
Identification No.)
301 Edgewater Place - Suite 100
Wakefield, Massachusetts 01880
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code: (978) 921-4125
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered under Section 12(b) of the Exchange Act: none
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On December 30, 2022, Leo Ehrlich, Chief Executive Officer of Innovation Pharmaceuticals Inc. (the “Company”), surrendered 11,307,527 shares of the Company’s Class B common stock to the Company for individual tax planning purposes. Mr. Ehrlich received no consideration for the surrender of the shares.
Following the surrender of the shares, 4,333,936 shares of Class B common stock remain outstanding, all of which are held by Mr. Ehrlich. Each share of Class B common stock entitles the holder to ten votes per share and each share of Class A common stock entitles the holder to one vote per share on all matters submitted to the Company’s stockholders for a vote. The Class B common stock is convertible at any time by the holder into shares of Class A common stock on a share-for-share basis.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INNOVATION PHARMACEUTICALS INC.
Dated: January 4, 2023 By: /s/ Leo Ehrlich
Name:
Leo Ehrlich
Title: Chief Executive Officer
(4)
(1)